LHLi-Li Huang

Li-Li Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Li-Li Huang has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An ROS-responsive photosynthetic biosystem disrupts the infectious-inflammatory-hypoxic cycle in pneumonia

    by Lili Huang, Zewei Yan, Kunpeng Li, Wenfeng Xu, Ruiqi Ming, Zhongjie Wang, Chuyu Li, Hanlin Chen, Shujun Liu, Yuantian Jing, et al.

    Acute lung injury (ALI) is sustained by a self-reinforcing cycle of inflammation, oxidative stress and hypoxia that current therapies cannot fully disrupt. To break this cycle, we engineered Haematococcus pluvialis (Hae) with chemiluminescent peroxyoxalate (CPPO) and fluorophore (Cy5) to construct a ROS-responsive photosynthetic biosystem (Hae@CC) for ALI therapy. Upon nebulization, excess H2O2 at the lesion triggers chemiluminescence (CL), which activates Cy5 through resonance energy transfer and drives endogenous Hae photosynthesis to produce oxygen (O₂) and the antioxidant astaxanthin (AST). In both lipopolysaccharide (LPS)- and bacteria-induced murine ALI models, aerosolized Hae@CC reduces bacterial load, alleviates pulmonary oedema and inflammation, promotes M2-biased macrophage polarization, enhances angiogenesis and improves pulmonary function, outperforming dexamethasone across multiple endpoints, with no appreciable toxicity in vivo. By correcting local hypoxia and redox imbalance, this biosystem resets the alveolar microenvironment, establishing that restoring homeostatic control, rather than blocking individual mediators, resolves inflammatory tissue injury.

  • Open Access

    Virosome-masked ratiometric nanoprobes for in vivo dynamic imaging of influenza a virus infection

    by Ruiqi Ming, Yue Wang, Zewei Yan, Shujun Liu, Zhongjie Wang, Hanlin Chen, Yingjie Shi, Yuantian Jing, Rui Zhang, Shasha Peng, et al.


  • Open Access

    Multistage responsive microneedle delivery system loaded oncolytic virus for topical therapy of melanoma

    by Zhongjie Wang, Zewei Yan, Hanlin Chen, Yue Wang, Yingjie Shi, Yuantian Jing, Ruiqi Ming, Shujun Liu, Pengfei Jin, Guanghao Wu, et al.


  • Open Access

    A nanosystem targeting tissue inhibitor of metalloproteinase-1 for continuous spatiotemporal idiopathic pulmonary fibrosis therapy

    by Chuyu Li, Guihong Lu, Hanlin Chen, Chenguang Wang, Zhongjie Wang, Ruiqi Ming, Shujun Liu, Lili Huang

    Idiopathic pulmonary fibrosis (IPF), a progressive, life-threatening disease marked by excessive collagen deposition, severe tissue injury, and dysregulated oxidative stress, poses a major threat to human health. Despite clinical advances, current therapies have limited anti-fibrotic efficacy. Here we show a reactive oxygen species (ROS)-responsive nanosystem targeting tissue inhibitor of metalloproteinase-1 (TIMP-1) for spatiotemporally precise IPF treatment. Anti-TIMP-1 antibodies (aT) are conjugated to mesenchymal stem cell-derived exosomes (Mexo) via ROS-cleavable phenylboronic acid ester linkers (cl), yielding Mexo-cl-aT. Following intratracheal administration, cl linkers are selectively cleaved by elevated ROS in the IPF microenvironment, enabling ROS scavenging while releasing Mexo and aT to mediate tissue repair and collagen degradation, respectively. We demonstrate that a single dose of Mexo-cl-aT exerts robust therapeutic efficacy against IPF in a bleomycin-induced mouse model of advanced-stage fibrosis, thereby validating this nanosystem as a safe and efficient candidate for next-generation IPF therapies.


  • Spatiotemporal STING activation via engineered bacterial vesicles enables safe and efficient cancer immunotherapy

    by Ruiqi Ming, Dingjie Suo, Zhongjie Wang, Shujun Liu, Chuyu Li, Chenguang Wang, Fan Zhang, Guihong Lu, Lin Mei, Li-Li Huang

  • Open Access

    Current status and future perspectives of multi‐modal bacteria‐based cancer therapies

    by Shuai Fan, Siyu Zhu, Wenyu Wang, Yuetong Liu, Yutong Zhou, Hao Li, Bofeng Liu, Qin Xia, Lili Huang, Lei Dong

    Background: Targeted drug delivery systems have garnered increasing research interest in cancer threapy. Bacteria have emerged as a promising vehicle due to their innate ability to the tumour microenvironment (TME) and their intrinsic immune‐stimulating properties. This review explores the application of bacteria in oncology, emphasizing the tumour‐targeting behaviour of specific strains, their immunomodulatory functions, and their potential as delivery platforms for the controlled release of therapeutic agents. Main text: This review synthesizes recent advances in bacteria‐mediated cancer therapy, focusing on the mechanisms underlying bacterial targeting of hypoxic and immunosuppressive regions within the tumor microenvironment (TME). We discuss how genetic modification has been employed to design recombinant bacterial strains with enhanced tumor specificity and amplified therapeutic effects. Furthermore, the integration of bacteria with nanotechnology has facilitated the development of hybrid systems capable of targeted drug delivery and triggered‐release mechanisms. The combination of bacterial therapy with other treatment modalities—such as photodynamic (PDT) and sonodynamic therapies (SDT)—is also examined, emphasizing their synergistic potential in overcoming tumor heterogeneity and enhancing anti‐tumor immunity. Finally, we survey the current clinical progress of bacteria‐based therapeutics and offer perspectives on the future role of artificial intelligence (AI) in improving the design and application of these living medicines. Conclusions: Bacteria‐based delivery systems represent a multifunctional and innovative strategy in the evolution of targeted cancer therapies. Through genetic modification and nanobiotechnology approaches, bacteria can be customized to mediate multi‐effect synergistic treatments for cancer, enhancing the precision, safety, and efficacy of cancer therapies. With the ongoing integration of advanced technologies, including AI, there is great potential to overcome existing limitations and accelerate the clinical translation of bacterial anticancer therapies. This interdisciplinary effort is poised to open new avenues for next‐generation cancer treatments and lay the foundation for future directions in cancer research and therapeutic practice. Key points: Bacteria exhibit inherent tumour‐targeting capabilities, particularly thriving in hypoxic tumour microenvironments (TMEs) and activating potent anti‐tumour immune responses through pathogen‐associated molecular patterns (PAMPs) and immunomodulation. Genetic engineering and nanobiotechnology enable advanced bacterial therapies, allowing for reduced toxicity, controlled proliferation, targeted drug delivery and the expression of therapeutic payloads (e.g., cytokines, enzymes, tumour antigens) within tumours. Bacteria serve as versatile platforms for multi‐modal synergistic therapy, effectively combining with immunotherapy, photodynamic therapy (PDT), thermodynamic therapy (TDT), photothermal therapy (PTT) and sonodynamic therapy (SDT) to significantly enhance tumour eradication. Artificial intelligence (AI) is poised to revolutionise bacterial cancer therapy, offering powerful tools for optimising synthetic biology designs (e.g., promoters, gene circuits), nanocarrier engineering and predicting bacterial–host interactions for more effective and safer treatments.


  • Open Access

    A self-adjuvant multiantigenic nanovaccines simultaneously activate the antiviral and antitumor immunity for the treatment of cancers

    by Zhongjie Wang, Hanlin Chen, Ruiqi Ming, Weiwei Wang, Shujun Liu, Yuantian Jing, Zewei Yan, Guihong Lu, Li-Li Huang

    Tumor cell-derived extracellular vesicles (tEVs) have garnered significant attention as promising antigen delivery vehicles for the development of cancer vaccines. However, their practical applications are hindered by weak immunogenicity and inadequate lymph node targeting. In this study, we engineered tEVs into “self-adjuvant” multiantigenic nanovaccines that simultaneously accumulate in tumors and lymph nodes (LNs), effectively triggering innate and adaptive immunity capable of recognizing both tumor cells and virus antigen-modified tumor cells to inhibit tumor progression. 4T1 tumor cells were infected with vesicular stomatitis virus (VSV), leading to the expression of VSVG and calreticulin (CRT) on their surface. Using these infected cells, we prepared extracellular vesicles (vEVs) carrying both VSVG and CRT. When injected subcutaneously, vEVs targeted tumors effectively due to the homologous targeting capability of tumor cell membranes. In which, VSVG induced fusion between vEVs and tumor cells, creating viral antigen-decorated tumor cells, which enhanced the recognition and phagocytosis of tumor cells by macrophages. Additionally, the surface CRT of vEVs activated the “eat-me” signaling, thus improving their recognition and uptake by dendritic cells (DCs). This led to DC maturation and the activation of antiviral and antitumor T cells, synergistically inhibiting tumor growth. This research introduces a straightforward yet efficacious methodology for the production of cancer vaccines to fight cancer through the stimulation of both the antiviral and antitumor immune responses within the body.


  • Engineered virus-mimicking nanovaccine with lymph node–tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy

    by Zhongjie Wang, Shujun Liu, Ruiqi Ming, Weiwei Wang, Chenguang Wang, Chuyu Li, Jiahua Yang, Fan Zhang, Guihong Lu, Lin Mei, et al.